Inflammatix
Burlingame · Founded 2016
About Inflammatix
Inflammatix develops novel molecular diagnostics for acute infections and sepsis that work by 'reading' the immune system. It is a molecular diagnostics company developing rapid tests that read the immune system to resolve major clinical and public health challenges. They are initially focused on developing tests for acute bacterial and viral infections, and sepsis based on patent-pending biomarkers exclusively licensed from Stanford University.
Company Facts
- Founded: 2016
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $194.8M
- Funding stage: Late Stage Venture
- Last round: Series E (Sep 2024)
- Website: https://www.inflammatix.com
- Phone: 650-443-3030
Industries & Categories
Bioinformatics, Biotechnology, Health Care, Health Diagnostics
Social Profiles
Canonical: https://fsome.com/organization/inflammatix-25390 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.